Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?

Pharmacopsychiatry

Volumn 43, Issue 2, 2010, Pages 73-80

  Schmauss M ^a   Diekamp, B ^b   Gerwe, M ^b   Schreiner, A ^b   Ibach, B ^b  

^a Bezirkskrankenhaus Augsburg   (Germany)

^b JANSSEN CILAG GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BIPERIDEN; CHLORPROTHIXENE; CITALOPRAM; DIAZEPAM; FLUOXETINE; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; MELPERONE; MIRTAZAPINE; OLANZAPINE; PIPAMPERONE; PROMETHAZINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL PATIENT; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTPATIENT; PARANOIA; PARKINSONISM; PATIENT SATISFACTION; PREMEDICATION; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SKIN DISEASE; SLEEP DISORDER; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949905574     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1239592     Document Type: Article

References (25)

1. Chue P, Eerdekens M, Augustyns I, etal. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005 15 111-117
2. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003 64 (Suppl 16) 18-23
3. Eerdekens M, Van Hove I, Remmerie B, etal. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Res 2004 70 91-100
4. Fleischhacker WW, Eerdekens M, Karcher K, etal. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 64 1250-1257
5. Guy W. ECDEU Assessment manual for psychopharmacology. Revised. Rockville, Maryland, USA: US Department of Health, Education and Welfare 1976 217-222
6. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004 18 113-132
7. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999 46 1396-1408
8. Kane JM, Aguglia E, Altamura AC, etal. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998 8 55-66
9. Kane JM, Eerdekens M, Lindenmayer J-P, etal. Long acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003 160 1125-1132
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bull 1987 13 261-276
11. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003 64 1308-1315
12. Keks NA, Ingham M, Khan A, etal. Long-acting injectable risperidone vs. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007 191 131-139
13. Lieberman JA, Stroup TS, McEvoy JP, etal. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005 353 1209-1223
14. Lindenmayer JP, Eerdekens E, Berry SA, etal. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicentre, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004 65 1084-1089
15. Marder SR. Overview of partial compliance. J Clin Psychiatry 2003 64 (Suppl 16) 3-9
16. Möller HJ, Llorca PM, Sacchetti E, etal StoRMi Study Group. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Intl Clin Psychopharmacol 2005 20 121-130
17. Naber D, Moritz S, Lambert M, etal. Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizophrenia Res 2001 50 79-88
18. Nasrallah HA, Duchesne I, Mehnert A, etal. Health-related quality of life in patients with schizophrenia during treatment with long acting, injectable risperidone. J Clin Psychiatry 2004 65 531-535
19. Tandon R, Belmaker RH, Gattaz WF, etal. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008 100 20-38
20. Valenstein M, Blow FC, Copeland LA, etal. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bull 2004 30 255-264
21. Walburn J, Gray R, Gournay K, etal. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001 179 300-307
22. Ware J, Snow K, Kosinski M. SF-36 Health survey manual and interpretation guide. Boston, Massachusetts. The Health Institute 1993
23. Weiden PJ, Kozma C, Grogg A, etal. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiat Serv 2004 55 886-891
24. Weiden J, Zygmunt A. Medication noncompliance in Schizophrenia, Pt 1: assessment. J Pract Psychiatry Behav Health 1997 106-111
25. World Health Organisation. International Classification of Diseases 10th Revision 1994